Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 643-651

  Abduljalil, K ^a,b   Frank, D ^a   Gaedigk, A ^c   Klaassen, T ^a   Tomalik Scharte, D ^a   Jetter, A ^a,d   Jaehde, U ^e   Kirchheiner, J ^f   Fuhr, U ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b CERTARA UK LIMITED   (United Kingdom)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; ANTITUSSIVE AGENT; DEXTRORPHAN;

ADULT; ALLELE; ARTICLE; CAUCASIAN; COMPARATIVE STUDY; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SCREENING; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GENE ACTIVITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; URINE PH; VOLUNTEER; BIOLOGICAL MODEL; BIOTRANSFORMATION; BLOOD; CLINICAL TRIAL (TOPIC); GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PH; PHENOTYPE; URINE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTITUSSIVE AGENTS; BIOTRANSFORMATION; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHENOTYPE; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 77958476379     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.137     Document Type: Article

References (45)

1. Moghadamnia, A.A., Rostami-Hodjegan, A., Abdul-Manap, R., Wright, C.E., Morice, A.H. & Tucker, G.T. Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. Br. J. Clin. Pharmacol. 56, 57-67 (2003).
2. Capon, D.A., Bochner, F., Kerry, N., Mikus, G., Danz, C. & Somogyi, A.A. The infuence of CYP2D6 polymorphism and quinidine on the disposition and antitussive efect of dextromethorphan in humans. Clin. Pharmacol. Ther. 60, 295-307 (1996).
3. Borges, S., Li, L., Hamman, M.A., Jones, D.R., Hall, S.D. & Gorski, J.C. Dextromethorphan to dextrorphan urinary metabolic ratio does not refect dextromethorphan oral clearance. Drug Metab. Dispos. 33, 1052-1055 (2005).
4. Jacqz-Aigrain, E., Funck-Brentano, C. & Cresteil, T. CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3, 197-204 (1993).
5. Barnhart, J.W. The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol. Appl. Pharmacol. 55, 43-48 (1980).
6. Chládek, J., Zimová, G., Beránek, M. & Martínková, J. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur. J. Clin. Pharmacol. 56, 651-657 (2000).
7. Frank, D., Jaehde, U. & Fuhr, U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur. J. Clin. Pharmacol. 63, 321-333 (2007).
8. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J. & Leeder, J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008).
9. Gaedigk, A., Bradford, L.D., Marcucci, K.A. & Leeder, J.S. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin. Pharmacol. Ther. 72, 76-89 (2002).
10. Laika, B., Leucht, S., Heres, S. & Steimer, W. Intermediate metabolizer: increased side efects in psychoactive drug therapy. The key to cost-efectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J. 9, 395-403 (2009).
11. Kirchheiner, J. et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473 (2004).
12. Kirchheiner, J., Keulen, J.T., Bauer, S., Roots, I. & Brockmöller, J. Efects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol. 28, 78-83 (2008).
13. Kirchheiner, J. et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 7, 257-265 (2007).
14. Kirchheiner, J. et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a frst step towards subpopulation-specifc dosages. Acta Psychiatr. Scand. 104, 173-192 (2001).
15. Schmid, B., Bircher, J., Preisig, R. & Küpfer, A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther. 38, 618-624 (1985).
16. Bock, K.W. et al. The infuence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, cafeine, and paracetamol as probes. Pharmacogenetics 4, 209-218 (1994).
17. Sachse, C., Brockmöller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
18. Steimer, W. et al. Allele-specifc change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. 50, 1623-1633 (2004).
19. Piotrovskij, V. & Van Peer, A. A model with separate hepato-portal compartment ("frst-pass" model): ftting to plasma concentration-time profles in humans. Pharm. Res. 14, 230-237 (1997).
20. Levi, M., Dempsey, D.A., Benowitz, N.L. & Sheiner, L.B. Population pharmacokinetics of nicotine and its metabolites I. Model development. J. Pharmacokinet. Pharmacodyn. 34, 5-21 (2007).
21. Florence, A.T. & Attwood, D. Physicochemical Principles of Pharmacy 4th edn (Pharmaceutical Press, London, 2006).
22. Costache, A.D., Trawick, D., Bohl, D. & Sem, D.S. Amine DB: large scale docking of amines with CYP2D6 and scoring for druglike properties-towards defning the scope of the chemical defense against foreign amines in humans. Xenobiotica. 37, 221-245 (2007).
23. Gotoh, O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 267, 83-90 (1992).
24. Yu, A., Kneller, B.M., Rettie, A.E. & Haining, R.L. Expression, purifcation, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J. Pharmacol. Exp. Ther. 303, 1291-1300 (2002).
25. Jiang, X.L., Shen, H.W. & Yu, A.M. Pinoline may be used as a probe for CYP2D6 activity. Drug Metab. Dispos. 37, 443-446 (2009).
26. Niwa, T. et al. Efect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res. Mol. Brain Res. 129, 117-123 (2004).
27. Bapiro, T.E., Hasler, J.A., Ridderström, M. & Masimirembwa, C.M. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem. Pharmacol. 64, 1387-1398 (2002).
28. Marcucci, K.A., Pearce, R.E., Crespi, C., Steimel, D.T., Leeder, J.S. & Gaedigk, A. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab. Dispos. 30, 595-601 (2002).
29. Hallifax, D. & Houston, J.B. Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems. Curr. Drug Metab. 10, 307-321 (2009).
30. Panserat, S., Sica, L., Gérard, N., Mathieu, H., Jacqz-Aigrain, E. & Krishnamoorthy, R. CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br. J. Clin. Pharmacol. 47, 121-124 (1999).
31. Toscano, C. et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988GA: evidence for modulation of splicing events. Pharmacogenet. Genomics 16, 755-766 (2006).
32. Raimundo, S. et al. A novel intronic mutation, 2988GA, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. 76, 128-138 (2004).
33. Kusama, M., Maeda, K., Chiba, K., Aoyama, A. & Sugiyama, Y. Prediction of the efects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. Pharm. Res. 26, 822-835 (2009).
34. Shen, H. et al. Comparative metabolic capabilities and inhibitory profles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos. 35, 1292-1300 (2007).
35. Duedahl, T.H., Dirks, J., Petersen, K.B., Romsing, J., Larsen, N.E. & Dahl, J.B. Intravenous dextromethorphan to human volunteers: relationship between pharmacokinetics and anti-hyperalgesic efect. Pain 113, 360-368 (2005).
36. Silvasti, M., Karttunen, P. , Tukiainen, H., Kokkonen, P. , Hänninen, U. & Nykänen, S. Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 25, 493-497 (1987).
37. Albers, G.W., Atkinson, R.P., Kelley, R.E. & Rosenbaum, D.M. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke. 26, 254-258 (1995).
38. Demirbas, S., Reyderman, L. & Stavchansky, S. Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers. Biopharm. Drug Dispos. 19, 541-545 (1998).
39. Labbé, L. et al. Efect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10, 425-438 (2000).
40. Fuhr, U. Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype? J. Clin. Pharmacol. 50, 370-372 (2010).
41. Klaassen, T. et al. Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. Eur. J. Clin. Pharmacol. 64, 387-398 (2008).
42. Tomalik-Scharte, D., Lütjohann, D., Doroshyenko, O., Frank, D., Jetter, A. & Fuhr, U. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin. Pharmacol. Ther. 86, 147-153 (2009).
43. Wyen, C. et al. Efect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin. Pharmacol. Ther. 84, 75-82 (2008).
44. Gaedigk, A. et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther. 81, 242-251 (2007).
45. Holford, N. Input-output models. In Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Perspective (eds. Kimko HC, Dufull SB) 2-31 (Marcel Dekker, New York, 2002).